There are lessons for other industries in the way pharma companies use mergers to innovate, work more efficiently, and bolster product portfolios.
The passage of US tax reform in late 2017 led to speculation that merger-and-acquisition activity would soon surge among pharmaceutical companies, due in part to tax-cut benefits accruing to sellers. Indeed, that has come to pass: in the first half of 2018, there were 212 deals in the sector worth more than $200 billion, up from 151 such deals in the year-earlier period.
Image: https://www.mckinsey.com
